ClinicalTrials.gg
CompletedNCT07038876Updated Jul 9, 2026

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

A Phase 2 interventional study of Placebo and ML-007C-MA BID in Schizophrenia, sponsored by MapLight Therapeutics. Completed at 24 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by MapLight Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
307
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,465 studies in Schizophrenia with a site in United States — 148 open to participants now, 166 under way, 22 of them phase 3. Schizophrenia · United States.

Enrollment
186th of 1,319
307 · median 66
Started
2025
with 41 others
Phase 2
217 of 1,465
11 open now
Registered
1,392nd of 1,465
by date

Among the 1,465 studies in Schizophrenia with a site in United States, this one is the 186th largest by enrollment of the 1,319 interventional ones that give a count, is one of 42 that started in 2025, is one of 217 in phase 2, and was the 1,392nd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

148 of the 1,465 studies in Schizophrenia with a site in United States are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,465 studies in Schizophrenia with a site in United States, or all of them as a file.
02

Study summary

ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis.

The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS) Total Score.

03

Conditions studied

  • Schizophrenia

Keywords

  • Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders
  • Mental Disorders
  • Psychotic Disorders
  • Schizophrenia
  • Muscarinic Antagonists
  • Muscarinic Agonists
  • Cholinergic Agents
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participant has a primary diagnosis of schizophrenia based on the criteria that is confirmed by semi-structured clinical interview (Mini International Neuropsychiatric Interview for DSM-5).
  2. Participant may benefit from hospitalization or is currently hospitalized due to an acute exacerbation of schizophrenia symptoms, with exacerbation onset within 2 months of Screening. If the participant is already hospitalized for acute exacerbation of schizophrenia at Screening, they must have been inpatient for less than 2 weeks at the start of Screening.
  3. At Screening and Baseline, schizophrenia symptoms are at least moderate in severity and persistent, as defined by the PANSS and CGI-S.
  4. Participant is willing and able to be confined to an inpatient setting for the study duration, follow instructions, and adhere to protocol requirements.

Key Exclusion Criteria:

  1. Participant has any DSM-5 disorder, other than schizophrenia, within 12 months before Screening that is primarily responsible for the current symptoms or functional impairment.
  2. Participant has any psychiatric hospitalization(s) for more than 30 days (cumulative) during the 90 days before Screening and/or current involuntary hospitalization or incarceration.
  3. Participant received any antipsychotic medication or prohibited therapy within the Screening Period unless discontinued before Baseline.
  4. Participant has current evidence of a and/or unstable medical comorbidity at Screening or Baseline.
  5. Participant is at an elevated risk of suicidal behavior.
  6. Participant has a known or likely allergy or other intolerance to ML-007C-MA, its active ingredients or their or has a known or likely severe allergic reaction (eg, anaphylactic reaction, angioedema) to any drug that could pose a risk to the participant in this study.
  7. Participant has a DSM-5 diagnosis of moderate to severe substance use disorder (except tobacco or caffeine use disorder) within the 12 months before Screening (confirmed using Mini International Neuropsychiatric Interview).
  8. Participation in a clinical research study involving the administration of an or marketed drug, biological product, or device within 90 days of Baseline, or concomitant active participation in an investigational study involving no drug, biological product, or device. Participants who have previously participated in a study with ML-007 may not participate.
  9. Participant is at elevated risk of violent or destructive behavior based on participant history and investigator judgment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
307 participants (actual)

Study arms

  • Experimental
    ML-007C-MA QD

    Drug: ML-007C-MA QD

  • Experimental
    ML-007C-MA BID

    Drug: ML-007C-MA BID

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to End of Treatment in Positive and Negative Syndrome Scale (PANSS) Total Score

    The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The total score is the sum of all scales with a minimum score of 30 and a maximum score of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

    Time frame: Baseline and End of Treatment (5 weeks)

Secondary outcomes

  1. Change From Baseline to End of Treatment in CGI-S score

    The CGI-S is a clinician-rated assessment of the severity of a participant's current illness on a 7-point scale, where a higher score is associated with greater severity. Values range from 1 (not ill at all) to 7 (among the most extremely ill).

    Time frame: Baseline and End of Treatment (5 weeks)

  2. Change From Baseline to End of Treatment in PANSS-Marder positive factor score

    The Positive Marder Factor score is derived from the PANSS and consists of the sum of 4 positive symptom items (P), one negative symptom item (N) and 3 general symptom items (G) (P1. Delusions; P3. Hallucinations; P5. Grandiosity; P6. Suspiciousness and persecution; N7. Stereotyped thinking; G1. Somatic concern; G9. Unusual thought content; G12. Lack of judgment and insight).

    Time frame: Baseline and End of Treatment (5 weeks)

  3. Change From Baseline to End of Treatment in PANSS-Marder negative factor score

    The Negative Marder Factor score is derived from the PANSS and consists of the sum of 5 negative symptom items (N) and 2 general symptom items (G) (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance), with a minimum score of 7 and a maximum score of 49.

    Time frame: Baseline and End of Treatment (5 weeks)

07

Study locations

24 sites
  • Clinical Site
    Little Rock, Arkansas 72211, United States
  • Clinical Site
    Bellflower, California 90706, United States
  • Clinical Site
    Culver City, California 90230, United States
  • Clinical Site
    Garden Grove, California 92845, United States
  • Clinical Site
    Lemon Grove, California 91945, United States
  • Clinical Site
    Los Angeles, California 90015, United States
  • Clinical Site
    Montclair, California 91763, United States
  • Clinical Site
    Orange, California 92868, United States
  • Clinical Site
    Riverside, California 92506, United States
  • Clinical Site
    San Diego, California 92123, United States
  • Clinical Site
    Sherman Oaks, California 91403, United States
  • Clinical Site
    Torrance, California 90504, United States
  • Clinical Site
    Hollywood, Florida 33024, United States
  • Clinical Site
    Miami Lakes, Florida 33016, United States
  • Clinical Site
    West Palm Beach, Florida 33407, United States
  • Clinical Site
    Atlanta, Georgia 30331, United States
  • Clinical Site
    Decatur, Georgia 30030, United States
  • Clinical Site
    Chicago, Illinois 60640, United States
  • Clinical Site
    Marlton, New Jersey 08053, United States
  • Clinical Site
    Staten Island, New York 10314, United States
  • Clinical Site
    North Canton, Ohio 44720, United States
  • Clinical Site
    Austin, Texas 78754, United States
  • Clinical Site
    DeSoto, Texas 75115, United States
  • Clinical Site
    Richardson, Texas 75080, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Jun 2026, 11 months.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 11 months is below that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Jun 26, 2025
StartActual
Jun 27, 2025
Primary completionActual
Jun 4, 2026
CompletionActual
Jun 11, 2026
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07038876
Lead sponsor
MapLight Therapeutics
Responsible party
Sponsor
First posted
Jun 26, 2025
Start date
Jun 27, 2025
Primary completion
Jun 4, 2026
Completion
Jun 11, 2026
Last update
Jul 9, 2026

Study contacts

MapLight Therapeutics
study director · MapLight Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ML-007C

Start the discussion